Y
Yoshihiro Ishibashi
Researcher at Takeda Pharmaceutical Company
Publications - 38
Citations - 3365
Yoshihiro Ishibashi is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Peptide sequence & Peptide. The author has an hindex of 21, co-authored 38 publications receiving 3183 citations.
Papers
More filters
Journal ArticleDOI
Discovery and Characterization of a Eukaryotic Initiation Factor 4A-3-Selective Inhibitor That Suppresses Nonsense-Mediated mRNA Decay.
Misa Iwatani-Yoshihara,Masahiro Ito,Yoshihiro Ishibashi,Hideyuki Oki,Toshio Tanaka,Daisuke Morishita,Takashi Ito,Hiromichi Kimura,Yasuhiro Imaeda,Samuel Aparicio,Samuel Aparicio,Atsushi Nakanishi,Tomohiro Kawamoto +12 more
TL;DR: A novel eIF4A3 inhibitor that targets the EJC is developed from a high-throughput screening campaign based on chemical optimization of the lead compounds based on ATPase activity, which exhibited noncompetitive inhibition with ATP or RNA and high selectivity for eIF 4A3 over other helicases.
Journal ArticleDOI
Purification of acidic fibroblast growth factor from bovine omentum.
TL;DR: Two heparin binding growth factors with different molecular weight, 16.6 kD and 18.
Journal ArticleDOI
Production of Human PTH(1-34) via a Recombinant DNA Technique
Shizue Nakagawa,Y. Tamakashi,Yoshihiro Ishibashi,M. Kawase,Shigehisa Taketomi,Osamu Nishimura,Tsunehiko Fukuda +6 more
TL;DR: The production of hPTH(1-34) by site specific chemical cleavage of [Cys35]hPTH (1-84) obtained by a biotechnology technique is described and the product was indistinguishable from standard hP TH(1 -34) with respect to chemical and biological characterization.
Journal ArticleDOI
Identification of cytidine-5-triphosphate synthase1-selective inhibitory peptide from random peptide library displayed on T7 phage.
Kotaro Sakamoto,Yoshihiro Ishibashi,Ryutaro Adachi,Shin-ichi Matsumoto,Hideyuki Oki,Yusuke Kamada,Satoshi Sogabe,Yumi Zama,Junichi Sakamoto,Akiyoshi Tani +9 more
TL;DR: The first CTPS1‐selective inhibitory peptide CTpep‐3 was discovered and it is reported that this peptide acts by binding to the amidoligase (ALase) domain onCTPS1, which is expected to control lymphocyte proliferation and size expansion in inflammatory diseases.
Journal ArticleDOI
Assignment of disulphide bonds in synthetic endothelin-1 isomers by fast atom bombardment mass spectrometry.
TL;DR: Endothelin-1, a 21-residue vasoconstrictor peptide possessing four cysteinyl residues at positions 1, 3, 11 and 15, was synthesized by random oxidation of a tetrahydro-ET-1 and a method was developed to determine the disulphide structure of the isomers.